Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
Tiffany A Traina, MD, FASCO Memorial Sloan Kettering Cancer Center New York, New York
The management of metastatic triple-negative breast cancer (mTNBC) has been transformed by the introduction of multiple new therapies, most notably antibody-drug conjugates and immunotherapeutic strategies. To gain a deeper understanding of what these developments mean for patient care, I spoke with Dr Tiffany A Traina from Memorial Sloan Kettering Cancer Center about how she navigates the latest advances in mTNBC in her own clinic. I invite you to check out this practically oriented discussion, available in audio and video formats, and Dr Traina’s slide presentation reviewing the datasets that have informed some of the most notable recent breakthroughs in this field.
Dr Jacob Sands from Dana-Farber Cancer Institute will join me today at 5 PM to discuss small cell lung cancer. We will review findings that emerged from the 2024 World Conference on Lung Cancer and their real-world applicability to challenging cases of patients with this form of the disease.
Register here to attend this specialized educational webinar.
This activity is supported by an educational grant from Daiichi Sankyo Inc.
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Research To Practice designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program and up to 0.75 Medical Knowledge MOC points in the American Board of Surgery’s (ABS) Continuous Certification program. Participants will earn MOC and Continuous Certification points equivalent to the amount of CME credits claimed for the activity. Please note, this program has been specifically designed for the following specialties: medical oncology (ABIM) and complex general surgical oncology (ABS). For more information, please review the full CME information for this program available on our website.
